COLLECTiVE202
Vedanta is currently enrolling participants into a Phase 2 study of VE202 for patients with IBD.
COLLECTIVE202 is a double-blind, placebo-controlled, Phase 2 study to evaluate the safety, efficacy, and microbiota changes of VE202 in patients with mild to moderate ulcerative colitis (UC).
Trial overview:
VE202 is administered as oral capsules. Each capsule contains 16 strains of bacteria that are often found in the normal human intestine
- The study will enroll 100 participants (18 to 75 years of age) with an endoscopically confirmed diagnosis of UC at least 3 months prior to enrollment
- Participants will be evaluated for further eligibility and upon confirmation, will be randomly assigned to one of two groups
For more information about the study including contact details, please visit clinicaltrials.gov.
Previous VE202 trials
In a Phase 1 study in healthy volunteers, VE202 was generally safe and well tolerated at all doses and demonstrated durable and dose-dependent colonization.
For additional information on the Phase 1 study, please visit clinicaltrials.gov.
VE202 for Inflammatory Bowel Disease
Our lead GI inflammatory disease program, VE202, is an orally-administered defined bacterial consortium candidate consisting of sixteen strains of live commensal bacteria for the treatment of IBD. In contrast to existing therapies, which are directed at inhibiting an overactive immune response, VE202’s proposed mechanisms of action have the potential to address multiple contributors to IBD: immune dysregulation, mucosal damage, and gut dysbiosis.